PRD10: COST-EFFECTIVENESS OF AZITHROMYCIN AND CO-AMOXICLAV IN ACUTE SINUSITIS  by Karpov, O & Zaytsev, A
180 Abstracts
METHODS: A retrospective database study was con-
ducted to compare patient adherence and concomitant
oral steroid use among patients on oral 2 agonists or
leukotriene antagonist therapy. 
RESULTS: Consistent with our first hypothesis, patients
using antileukotrienes were more adherent than patients on
oral 2 agonists, over a 12-month period. However, con-
trary to our second hypothesis, patients using antileuko-
trienes were eight times more likely to be on concomitant
oral steroid therapy than patients using oral 2 agonists. 
CONCLUSIONS: These findings may reflect a “new
drug” effect: those patients whose disease is most diffi-
cult to control on existing therapies are placed on the
newest treatment, drug indications notwithstanding. Fi-
nally, the results of this study provide further evidence of
the utility of retrospective database studies to provide
healthcare providers with cost-effective information re-
flecting real-world patient behaviors.
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The prevalence of sinusitis has been increasing, as has been
the number of visits for the condition. Relatively little data
are available on its diagnosis, treatment and costs. 
OBJECTIVE: The purpose of this study is to analyze re-
sources utilized in the treatment of sinusitis, in particular
recurrent sinusitis. 
METHODS: The database of Fallon Community Health
Plan (FCHP), a Massachusetts-based group model HMO,
was analyzed to identify members with three or more vis-
its for sinusitis in an eighteen month period. A total of
495 patients were identified. Their utilization of primary
care physician (PCP) and specialty visits, procedures, an-
cillary services, costs of services, type, quantity, and cost
of drugs prescribed was analyzed. 
RESULTS: Of the patients, 76% were women and 24%
were men. Age ranged between 18 years and 91 years
(mean  45). The subjects had a total of 17,407 proce-
dures and diagnoses during the study period. In 31% of
visits, the subjects were treated by a PCP; in 8.5% visits
they were seen by an Allergist; and in 6.7% visits they
were seen by an ENT. The most frequent primary diag-
nosis was Allergic rhinitis (8.2%) followed by acute si-
nusitis (5.8%). The total cost of the utilization was
$1,052,678 (mean  $2127). The total number of pre-
scriptions filled during the study period was 13,539
(mean  27.35). The total cost of these prescriptions was
$446,879 (mean  $903). 
CONCLUSION: The treatment and management of pa-
tients with chronic sinusitis is more intensive than com-
monly realized. The present study provides insight into
demographics and the type and costs of treatment of this
patient group.
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Azithromycin is an azalide antibiotic with broad-spec-
trum activity; it has a prolonged biological half-life and
slow elimination from nasal sinuses. These features make
it possible to use azithromycin during short-term periods
that may be important for compliance. However, the eco-
nomic results have not been investigated. 
OBJECTIVE: The purpose of this study was to evaluate
the efficacy, safety and cost of therapy of azithromycin
and a course of co-amoxiclav in acute sinusitis in adults. 
METHODS: Among 100 adults with acute sinusitis, 50
were randomized to receive azithromycin 500 mg once daily
for 3 days (group I), and 50 co-amoxiclav 625 mg tid for 10
days (group II). Clinical examination was performed at base-
line and 72 hours, 10–12 and 26–30 days after treatment ini-
tiation. Each sign and symptom was scored and clinical find-
ings were expressed by total clinical score (TCS). TCS was
significantly lower in group I after 72 hours following treat-
ment start and at 10–12 days. Cost analysis included drug
price, physician cost, and cost of hospitalization. 
RESULTS: At 10–12 days of therapy, 41 (82%) patients
in group I and only 26 (52%) in group II were free of
symptoms associated with increased duration and cost of
hospitalization. By the follow-up assessment, satisfactory
clinical response was indicated in both groups. The aver-
age cost of treatment for group I was $116 and in group II,
$150 per patient. During a half-year, relapse of sinusitis
was marked in 16% of cases in group II and the additional
treatment charges made on average $170 per patient. 
CONCLUSION: The treatment 3-day azithromycin is as
effective as 10-day co-amoxiclav, but azithromycin pro-
vides faster clinical effect and does not lead to relapse,
with better pharmacoeconomic outcomes.
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Allergic rhinitis can cause a severe decrease in a sufferer’s
quality of life. Many non-sedative antihistamines have
demonstrated efficacy in phase I through III trials. How-
ever, patients’ quality of life during treatment had not
been measured or evaluated. 
OBJECTIVE: The purpose of this study was to determine
if quality of life improves during a 3-week time period
while patients were being treated with loratadine for al-
lergic rhinitis. 
METHODS: Twenty-five patients with diagnosed aller-
gic rhinitis were treated with loratadine 10 mg every
